Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 1,216,585 | 1,140,820 | 1,090,579 | 1,105,239 | 1,109,457 |
| Cost of Goods | 437,498 | 418,081 | 432,465 | 421,885 | 414,725 |
| Gross Profit | 779,087 | 722,739 | 658,114 | 683,354 | 694,732 |
| Operating Expenses | 354,019 | 360,234 | 342,974 | 329,393 | 322,411 |
| Operating Income | 425,566 | 362,586 | 315,605 | 354,846 | 373,046 |
| Interest Expense | 10,182 | 7,741 | 9,210 | 10,655 | 11,321 |
| Other Income | 1,840 | 597 | 587 | 580 | 627 |
| Pre-tax Income | 417,224 | 355,442 | 306,982 | 344,771 | 362,352 |
| Income Tax | 78,812 | 76,996 | 58,794 | 70,161 | 68,363 |
| Net Income Continuous | 338,412 | 278,446 | 248,188 | 274,610 | 293,989 |
| Net Income | $338,412 | $278,446 | $248,188 | $274,610 | $293,989 |
| EPS Basic Total Ops | 4.29 | 3.50 | 3.10 | 3.43 | 3.66 |
| EPS Basic Continuous Ops | 4.29 | 3.50 | 3.10 | 3.43 | 3.66 |
| EPS Diluted Total Ops | 4.27 | 3.47 | 3.09 | 3.40 | 3.63 |
| EPS Diluted Continuous Ops | 4.27 | 3.47 | 3.08 | 3.40 | 3.63 |
| EPS Diluted Before Non-Recurring Items | 4.27 | 3.47 | 3.08 | 3.40 | 3.63 |
| EBITDA(a) | $466,617 | $400,269 | $354,326 | $391,473 | $408,818 |